Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Ipilimumab (Primary) ; Tretinoin (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 06 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Feb 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.